---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-168351"
form_type: "8-K"
ticker: "JBIO"
cik: "0001798749"
company_name: "Jade Biosciences, Inc."
filed_at: "2026-04-22T23:59:59+00:00"
generated_at: "2026-05-15T04:54:55.470481+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "high"
source: SEC EDGAR
---

# Andrew King promoted to President, R&D at Jade Biosciences

## Summary
- Andrew King previously CSO and Head of R&D appointed President Research & Development effective April 18 2026
- No changes to Dr Kings compensation were made in connection with the appointment
- King holds BVMS and Ph.D degrees and continues to lead R&D with expanded title

## SEC filing metadata
- accession: 0001193125-26-168351
- form_type: 8-K
- ticker: JBIO
- cik: 0001798749
- company_name: Jade Biosciences, Inc.
- filed_at: 2026-04-22T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1798749/000119312526168351/0001193125-26-168351-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1798749/000119312526168351/d90643d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-168351
- JSON: https://secwatch.observer/filing/0001193125-26-168351.json
- Plain text: https://secwatch.observer/filing/0001193125-26-168351.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.